ScreenPoint Medical

ScreenPoint Medical develops Transpara Breast AI, an FDA-cleared and CE-marked artificial intelligence platform for 2D and 3D mammography. The company specializes in AI-driven breast cancer detection and clinical workflow optimization. Transpara Detection is the flagship product, engineered to assist radiologists in finding malignancies earlier while reducing reading time and workload. The platform offers vendor-agnostic compatibility with existing mammography systems (FFDM and DBT), supporting single and double reading environments. Published randomized controlled trials demonstrate a 29% increase in cancer detection and 44% reduction in radiologist workload. Transpara also offers complementary applications including Density assessment (BI-RADS-like volumetric analysis) and Temporal Comparison (prior mammogram tracking across 9 months to 6.5 years). The company serves breast imaging programs, diagnostic centers, and academic medical institutions across 30+ countries. ScreenPoint emphasizes clinical validation through peer-reviewed publications and participation in multiple prospective randomized controlled trials (MASAI, PRISM). The platform targets addressing critical healthcare challenges including radiologist shortages, staff burnout, and rising diagnostic volumes while supporting precision medicine and personalized screening protocols.